Status:
COMPLETED
Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.
Lead Sponsor:
Xuanwu Hospital, Beijing
Conditions:
Cerebral Venous Thrombosis
Eligibility:
All Genders
14+ years
Brief Summary
The cohort study aims to evaluate the efficacy and safety of steroids combined with anticoagulant therapy compared to standard anticoagulant therapy in acute/subacute severe cerebral venous thrombosis...
Detailed Description
Background: Evidence suggests that the inflammatory response plays a crucial role in regulating severe CVT pathogenesis. However, whether CVT patients can benefit from anti-inflammatory therapy has be...
Eligibility Criteria
Inclusion
- Acute or subacute severe CVT, determined by the onset-to-admission time (≤ 15 days) or symptom aggravation-to-admission time (≤ 15 days) and MRI+MRV/MRBTI (MR Black-Blood Thrombus Imaging), or CT+CTV
Exclusion
- younger than 14 years；
- foreign nationality；
- receiving steroids before the onset of CVT；
- patients with other serious diseases；
- Presenting with neurological deficits before the onset of CVT；
- lack of baseline data before treatment；
- receiving steroids during hospitalization for other reasons but the dosage did not reach pulsed-therapy level
- brain herniation but refusing to undergo decompressive craniectomy, or pupillary light reflex did not recover after decompressive craniectomy
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2024
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT05990894
Start Date
July 1 2020
End Date
July 31 2024
Last Update
July 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xuanwu Hospital, Capital Medical University
Beijing, China